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Background: The aim of this study was to determine if variable number of tandem repeats (VNTR) in the second
intron (STin2) of the serotonin transporter (SLC6A4) gene was associated with tobacco use disorder, successful
smoking cessation, or smoking characteristics. In this case–control study, patients with current tobacco use disorder,
diagnosed according to DSM IV criteria (n = 185), and never-smokers, diagnosed according to CDC criteria (n = 175),
were recruited and received 52 weeks of combined pharmacotherapy and cognitive therapy. Successful smoking
cessation was defined as exhaled carbon monoxide < 6 ppm. SLC6A4 gene STin2 VNTR polymorphism was assessed
using a Multiplex-PCR-based method. At baseline, participants were evaluated using the Fagerström Test for Nicotine
Dependence (FTND) and the ASSIST scale.
Results: The STin2.12 allele (OR = 2.45; 95% CI = 1.44-4.15, p < 0.001) was associated with an increased risk for tobacco
use disorder, while the STin2.10/10 genotype (OR = 0.42; 95% CI 0.25-0.71, p < 0.001) decreased risk. There
were no significant associations between tobacco use disorder and the STin2.10 or STin2.9 alleles or the other
genotypes (STin2.12/12, 12/10, 12/9, 10/9 or 9/9). There were no significant associations between the STin2
genotypes and alleles and successful smoking cessation, smoking characteristics and increased alcohol or
sedative use risk.
Conclusions: Our results suggest that the STin2.10/10 genotype and STin2.12 allele are associated with tobacco
use disorder or nicotine dependence, but not with treatment response or severity of dependence. It is
hypothesized that the ST2in.12 allele by modulating the metabolism of serotonin may participate in the
pathophysiology of tobacco use disorder or nicotine dependence.
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Tobacco use disorder is a leading cause of mortality and
disease burden [1,2]. Tobacco use disorder is a complex
behavior that includes a number of stages of addiction,
such as vulnerability to onset of use, continued use, pro-
pensity to become dependent and tobacco withdrawal
[3-5]. 19% of ever smokers convert to daily smoking by
the age of 15 years and 10% progress to smoking 20 cig-
arettes or more per day by the age of 18 [3]. Quitting
smoking is beneficial to health at any age. Cigarette
smokers who quit before age 35 years have mortality
rates similar to those who never smoked. It is estimated
that about 68.8% of adult smokers want to stop smoking,
52.4% attempted to quit in the past year, 6.2% had quit
recently, 48.3% had been advised by a health professional
to quit, and 31.7% had used counseling and/or medica-
tions when they tried to quit [4]. More than 80% of indi-
viduals who have tobacco use disorder attempt to quit
smoking. 60% of the quitters, however, relapse within
one week and less than 5% remain in sustained remis-
sion during a period of 12 months or longer.
Genetic factors and heritability contribute strongly to
the onset of tobacco use and the development of tobacco
use disorder [5]. Serotonin and the serotonin transporter
(5-HTT) are implicated in the pathophysiology of to-
bacco use disorder [6]. The SLC6A4 gene is located on
chromosome 17 and three polymorphisms have been de-
scribed: an insertion deletion in the promoter region,
called 5-HTTLPR (serotonin transporter linked poly-
morphic region), a SNP G-T polymorphism in a non-
coding 3 ′UTR, and the STin2 polymorphism, which is
a 17 bp variable number of tandem repeat (VNTR) lo-
cated in the second intron in SLC6A4 [7]. The SLC6A4
gene is the most frequently studied polymorphism in de-
pression and tobacco use disorder [8,9]. The same gene
may in part determine vulnerability for depression when
exposed to multiple life stressors [10]. A study in 185
current smokers showed a positive association between
neuroticism, an anxiety–related personality trait, and
smoking behaviors and the S expression of the 5-HTTLPR
region, but not the L genotype [11].
While there are now many reports on the association
between 5-HTTLPR polymorphism of the SLC6A4 gene
and smoking behavior [11-25], there are only few studies
on the SLC6A4 gene STin2 polymorphism in tobacco
use disorder [7,26]. The STin2 allelic variants were iden-
tified as 10-repeat and 12-repeat alleles that have been
identified in all ethnicities, and the less common 9-
repeat allele was only found in individuals of European
or African descent [27]. An altered function of the STin
2 VNTR in the SLC6A4 gene may be involved in tobacco
use disorder since the STin2.12 allele has been reported
to be a transcriptional enhancer associated with suscep-
tibility to substance abuse [28]. It is now well establishedthat nicotine increases serotonergic neurotransmission
in the brain and symptoms of nicotine withdrawal may be
mediated by a lowered serotonergic neurotransmission
[7,29]. The STin2 polymorphism has also been associated
with cognitive dysfunction in major depression [30].
Interestingly, the serotonin system and the SLC6A4
gene have been implicated in the pathophysiology of
psychiatric disorders which show a strong comorbidity
with tobacco use disorder, including mood disorders and
alcohol abuse [6,31]. Tobacco use and mood disorders
are commonly comorbid conditions in patients of
cigarette smoking cessation treatments [15,32-36]. In de-
pressed smokers, depletion of serotonin in the brain is
associated with a high risk for suicide and attempted sui-
cide [35,37]. The short allele of 5-HTTLPR and the 12
repeat allele of STin2 are associated with a history of
suicide attempts [38]. The serotonergic system has been
associated with several personality traits that are related
to an increased incidence of smoking, increased nicotine
dependence, and difficulty in quitting smoking [39].
The aim of this paper was to delineate whether STin2
polymorphism of the SLC6A4 gene is associated with a)
tobacco use disorder, b) successful smoking cessation, c)
smoking characteristics, including age at onset of tobacco
use, duration of illness, lifetime cigarette consumption,
years of smoking, severity of nicotine dependence, and d)
comorbid substance use disorders, including alcohol and
sedative abuse.
Methods
Cases and controls
In this case–control study, patients with current tobacco
use disorder (n = 185) were recruited from outpatients at
the Center of Approach and Treatment for Smokers, a
smoking cessation program at Londrina State University
(UEL), Paraná, Brazil. The controls were never-smokers
(n = 175), recruited from staff at UEL. Patients with to-
bacco use disorder and never-smokers were men and
women aged 18–65 and all ethnicities were accepted for
this study. The diagnosis of tobacco use disorder was
made by a senior psychiatrist using the semi-structured
(SCID) interview translated into Portuguese [40]. In this
study we only included current smokers who had
smoked at least 100 cigarettes during their lifetime and,
at the time of the interview, reported smoking every day
or some days [41]. The controls, i.e. never-smokers, were
subjects without tobacco use disorder who reported that
they had never smoked a cigarette over their lifetime.
Our never-smokers criteria are thus more stringent than
the CDC criteria (41) for never-smokers, i.e. individuals
who smoked less than 100 cigarettes in their lifetime. Cases
with lifetime axis 1 diagnoses other than tobacco use
disorder and affective disorders were excluded, including
schizophrenia and psycho-organic syndromes. Patients
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disorders were also excluded, including Parkinson’s
disorder, stroke, multiple sclerosis, lupus erythemato-
sus, rheumatoid arthritis, COPD, etc. The same exclu-
sion criteria were applied to the never-smokers. The
sample size was based on an a priori power calculation,
which considered that with a power of 0.8, an effect
size of 0.15 and α = 0.05 the total sample size should be
around 350. A self-reported questionnaire was used to
obtain information on socio-demographic characteris-
tics, such as age, gender, marital status, ethnicity, years
of education, and employment status. The study was
conducted from March 2011 to July 2012. All subjects
gave written informed consent to participate in the
study after approval by the Ethics Research Committee
at UEL, number 037/2011.
Smoking characteristics
Smoking behavior was assessed through an interviewer-
administered structured questionnaire. The Fagerström
test for Nicotine Dependence (FTND) [42], translated
and validated for use in Portuguese [43], was adminis-
tered to all patients with tobacco use disorder. The
FTND produces a score ranging from 0 to 10. Nicotine
dependence was defined as a score ≥ 6 [44]. The number
of pack-years was calculated as the number of cigarettes
smoked per day multiplied by number of years smoked
and divided by 20 (1 pack has 20 cigarettes).
Smoking status was also evaluated using exhaled car-
bon monoxide (COEXH). COEXH was measured using a
Micro CO Meter with an electrochemical sensor (Micro
CO- Micro Medical Ltd, Rochester, Kent, UK). All
participants were instructed to breathe deeply and to hold
their breath for 20 seconds and then to exhale slowly and
completely through a mouthpiece. The COEXH levels were
dichotomized using 6 ppm as threshold value [45].
This threshold value was used as an additional inclusion
criterion. Thus, never-smokers all had COEXH < 6 ppm,
whereas those with current tobacco use disorder had a
COEXH ≥ 6 ppm.
Successful smoking cessation
All cases were treated for a period of 52 weeks with cog-
nitive behavioral therapy sessions administered to groups
of 10–15 participants and lasting for about 1½ hours.
After the patient received an individualized assessment
with the physician, he/she attends four weekly group
sessions followed by two biweekly group sessions and
then monthly sessions for a period of 52 weeks. Parallel
to these group sessions, patients also receive pharma-
cological intervention, bupropion or nicotine replace-
ment therapy, in accordance with the guidelines of the
Ministry of Health, Brazil [46,47]. The combined pro-
gram of tobacco use-focused cognitive therapy andpharmacological treatment is effective for both genders
and depressed and non-depressed smokers [15]. Suc-
cessful smoking cessation was assessed at the end of
the treatment period as exhaled breath COEXH < 6 ppm. 64
of 185 subjects with tobacco use disorder were able to quit
smoking during our 52 week treatment program.
Substance use disorders
We used the Alcohol, Smoking and Substance Involve-
ment Screening Test (ASSIST), which was developed by
the World Health Organization, to screen levels of risk
for alcohol and sedative use. We computed ASSIST
scores for all participants. A risk score for alcohol was
estimated as low risk (score 0–3), moderate risk (score
11–26) or high risk (score ≥ 27) and a risk score for sed-
atives was calculated as low risk (score 0–3), moderate
risk (score 4–26) or high risk (score ≥ 27) [48]. The diag-
noses of mood disorders, that is depressive disorder and
bipolar disorder, was made by a trained psychiatrist
using the semi-structured DSM-IV interview (SCID)
using a validated Portuguese translation [40]. There were
112 individuals diagnosed with depression and 45 with
bipolar disorder.
Genotyping
Peripheral blood samples were obtained with EDTA as
anticoagulant from all participants. Genomic DNA was
extracted from 200 μL of peripheral blood cells using
the Biopur Kit (Biometrix Diagnostic, Curitiba, Brazil)
according to the manufacturer's instructions. The DNA
pellet was re-suspended in 50 μL of Biopur Kit specific buf-
fer, quantified by spectrophotometry, and stored in a -20°C
freezer until use in genotyping analyses. Allelic Specific
polymerase chain reaction (AS-PCR) for STin2 VNTR
polymorphism detection were realized with genomic DNA
(100 ng) with specific primers described by [48]. Forward
primer — 5′TGGATTTCCTTCTCTCAGTGAATTGG3′
and Reverse primer —5′TCATGTTCCTAGTCTTACGC-
CAGTG3′. Samples were amplified using the kit buffer
plus 1.25 units Taq polymerase (Invitrogen TM, Carlsbad,
California). PCR conditions were: 5 min denaturation at
94°C, 40 cycles of 1 min at 94°C, 1 min at 60°C and 1 min
at 72°C, and 20 min elongation at 72°C in a Master Cycler (
Eppendorf, Hamburg, Germany). Amplicons were analyzed
by electrophoresis in 10% polyacrylamide gel and detected
by a non radioisotopic technique using a commercially
available silver staining method.
Statistical analyses
The gene frequencies observed in patients with tobacco
use disorder and never- smokers were compared using
analyses of contingency tables (χ2 tests) with calculation
of the Odds Ratios (OR) with a 95% confidence interval
(CI). We used bivariate logistic regression analyses to
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(with the controls as reference group) as dependent vari-
able and the STin2 alleles and genotypes as explanatory
variables, while controlling for the effects of other ex-
planatory variables, including mood disorders, BMI,
ethnicity, age, gender, years of education, etc. We used
the logistic regression coefficients of the independent
variables as estimators of the OR with 95% CIs. Relation-
ships between the STin2 alleles and genotypes and
continuous variables (e.g. age, years of education) were
examined using analyses of variance (ANOVAs). Associ-
ations between diagnostic groups (cases versus controls)
or gene frequencies and socio-demographic and clinical
data were examined using contingency tables or Fisher
exact probability test. Data have been expressed as mean ±
standard deviation (SD). All the analyses were performed
using SPSS (Version 20). A significance level of p-values ≤
0.05 was used for statistical significance.
Results
Socio-demographic and clinical characteristics
Table 1 shows the socio-demographic and clinical char-
acteristics of patients with current tobacco use (cases)
and never-smokers (controls). No p-correction was
employed to assess the results of multiple statistical uni-
variate analyses carried out on the clinical and socio-Table 1 Socio-demographic and clinical characteristics of pati
smokers
Variables Smokers (n
Age (mean ± SD) 48.7 (±10.5)
Gender Female/male 119/66
Self-reported ethnicity
Caucasian 129
African 19
Asian 5
Others 32
Years of education 9.64 (±5.38)
Employment status
Employed or student versus unemployed or disability support 155/30
Stable relationship versus other
Marital status 113/72
BMI (kg/m2) 26.6 (±5.9)
Mood disorders Yes/no 95/90
ASSIST sedative use risk Yes/no 14/171
ASSIST alcohol use risk Yes/no 33/152
ASSIST ALL Yes/no 44/141
Results of analyses of variance (ANOVAS: age, BMI), χ2 test (ethnicity, gender, marita
all ASSIST ratings).
Results are shown as mean ± SD.
BMI: Body Mass Index.
ASSIST: Alcohol, Smoking and Substance Involvement Screening Test.
ASSIST ALL: sedative or alcohol use risk.demographic data because we used these results to de-
lineate the relevant explanatory variables that were used
as determinants of independent association with the
diagnostic groups in multivariate analyses. Without
p-correction, we found that there were significant differ-
ences in age between patients with tobacco use disorder
and never-smokers. There were no significant differences
in gender ratio or ethnicity between the two groups.
Subjects with tobacco use disorder had a lower level of
education than controls. In patients with tobacco use
disorders there were more subjects who were un-
employed or received disability support payments than
in the control group. There were no differences in mari-
tal status and BMI between both groups. Patients with
tobacco use disorder showed more mood disorders, and
alcohol use and sedative use risk (and use of alcohol or
sedatives) than never-smokers.
Association between tobacco use disorder and STin2
alleles and genotypes
Table 2 shows the association between the Stin2 VNTR
polymorphism and tobacco use disorder. The associa-
tions between tobacco use disorder and the 6 STin2
genotypes were tested at p = 0.0083 and those with the
three STin2 alleles at p = 0.0166 (after p-correction was
made for multiple comparisons). We found a significantlyents with current tobacco use disorder (TUD) and never-
= 185) Never-smokers (n = 175) χ2/F/ Ψ df p value
45.7 (±7.7) 9.78 1/358 p < 0.002
120/55 0.73 1 0.394
119 3.55 1 0.315
17
12
27
15.98 (±4.94) 135.78 1/358 p < 0. <0.001
175/0 0.293 - <0.001
Pp0 0.109
121/54 2.57 1
26.5 (±4.2) 0.20 1/358 0.887
62/113 9.27 1 0.002
0/175 0.196 - <0.001
0/175 0.309 - <0.001
0/175 0.363 - <0.001
l status, mood disorders) or Fisher exact probability test (employment status,
Table 2 STin2 VNTR polymorphism in patients with tobacco use disorder (TUD) versus never-smokers
STin2 VNTR Never-smokers n = 175 TUD n = 185 OR 95% CI χ2 p
Yes No Yes No
Genotypes STin2 - 12/12 72 103 82 103 0.88 0.58-1.33 0.54 0.372
STin2 - 12/10 50 125 71 114 1.56 1.00-2.42 3.88 0.049
STin2 - 12/9 3 172 6 179 0.63 0.15-2.67 0.72 0.353
STin2 - 10/10 49 126 26 159 0.42 0.25-0.71 10.60 < 0.001
STin2 - 10/9 0 175 0 185 - - - -
STin2 - 9/9 1 174 0 185 - - - -
Allelic Variants STin2.12 125 50 159 26 2.45 1.44-4.15 11.38 < 0.001
STin2.10 99 76 97 88 0.85 0.56-1.28 0.621 0.431
STin2.9* 4 171 6 179 1.43 0.40-5.17 - 0.751
OR: odds ratio with 95% CI: confidence interval). All results of χ2 tests (df = 1), except * result of Fisher exact probability test.
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cantly higher frequency of the STin2.12 allele in patients
with tobacco use disorder versus never-smokers. There
were no significant differences in any of the other geno-
types or for STin2.9 and STin2.10 alleles between cases and
controls.
Table 3 shows the results of logistic regression analyses
with tobacco use disorder as dependent variable (and
controls as reference group) and the STin2.12 allele and
STin2.10/10 genotype, age, gender, education, mood dis-
orders, as explanatory variables. We found that the
STin2.12 allele, the diagnosis of mood disorders and
years of education predicted the incidence of tobacco
use disorder versus never-smokers (χ2 = 141.61, df = 3,
p < 0.001; Nagelkerke = 0.43). Forced entry of additional
explanatory variables showed no significant effect of age
(Wald = 1.91, df = 1, p = 0.167), gender (Wald = 1.24,
df = 1, p = 0.266), self-reported ethnicity (Wald = 5.00,
df = 1, p = 0.288), marital status (Wald = 2.21, df = 3, p =
0.529) and BMI (Wald = 1.58, df = 1, p = 0.209). There
was a marginal, but significant effect of employment sta-
tus (Wald = 4.01, df = 1, p = 0.045). We found that the
STin2.10/10 genotype, mood disorders and years of edu-
cation were associated with the incidence of tobacco use
disorder versus never-smokers (χ2 = 141.64, df = 3, p <Table 3 Results of automatic (step-up) binary logistic regressi
dependent variable (never-smokers as reference group) and
(regression 2) and the other listed variables as explanatory v
Variables Wald
Regression 1 STin2.12 allele 8.68
Mood disorders 6.51
Years of education 72.98
Regression 2 STin2.10/10 genotype 8.14
Mood disorders 6.64
Years of education 72.99
OR: odds ratio with 95% CI: 95% confidence interval.0.001; Nagelkerke = 0.43). Forced entry of additional ex-
planatory variables showed no significant effect of age,
gender, self-reported ethnicity, marital status and BMI.
There was a marginal but significant association between
tobacco use disorder and employment status (Wald =
5.41, df = 1, p = 0.020). Thus, adjusting for additional
relevant explanatory variables, including mood disorders,
did not change the associations between tobacco use dis-
order and STin2 alleles and genotypes, and revealed that
mood disorders and years of educations were significant
predictors.
Association between smoking characteristics and STin2
alleles and genotypes
We have also computed whether, in patients with to-
bacco use disorder, there were associations between
STin2 VNTR genotypes and alleles and successful smok-
ing cessation 52 weeks after starting treatment and
smoking characteristics, i.e. age at onset of tobacco use
disorder, duration of illness, cigarettes/day and pack/
years, the FNDS score and attempts to quit smoking.
Table 4 shows the associations between the STin2 poly-
morphism and smoking cessation and smoking charac-
teristics. Even at very liberal p-values (p-correction for
multiple comparisons) of p = 0.0083 (for the genotypes)on analyses with tobacco use disorder (TUD) as
the STin2.12 allele (regression 1) or STin.10/10 genotype
ariables
df p value OR 95% CI
1 0.003 2.68 1.39 – 5.18
1 0.011 1.97 1.17 – 3.32
1 <0.001 0.76 0.71 – 0.81
1 0.004 0.38 0.20 – 0.74
1 0.010 1.98 1.18 – 3.34
1 <0.001 0.76 0.71 – 0.81
Table 4 Associations between tobacco use disorder (TUD) characteristics and STin2 VNTR genotypes and allelic
variants
Smoking parameters Genotypes Allelic variants
STin2 10/10 STin2 12/10 STin2 12/12 STin2.12 STin2.10
n P* P* P* P* P*
Onset of TUD (years) 14.81 (±3.91) 185 0.868 0.170 0.156 0.868 0.146
Duration of TUD (years) 33.59 (±11.28) 185 0.061 0.262 0.478 0.061 0.837
Cigarettes/day 22.28 (±13.45) 185 0.120 0.987 0.377 0.120 0.274
Pack-years 37.02 (±28.11) 185 0.017 0.617 0.239 0.017 0.247
Fagerström score 5.71 (±2.21) 185 0.361 0.670 0.591 0.361 0826
Attempts at smoking cessation 1, 2 or 3 attempts 86/67/32 0.948 0.852 0.728 0.948 0.739
Successful smoking cessation Yes/no 64/185 0.658 0.858 0.612 0.658 0.630
Results are shown as mean ± SD.
*p values obtained in analyses of variance (all df = 1/183) or χ2 tests (all df = 1).
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any significant associations between the STin2 VNTR
genotypes and alleles and successful smoking cessation
and clinical smoking characteristics.
Comorbidities with substance use risk
Table 1 shows that participants with tobacco use dis-
order had significantly higher scores on the sedative and
alcohol ASSIST scales than participants without tobacco
use disorder. Nevertheless, we could not find any rela-
tionships between the STin2.12 allele or the STin2.10/10
genotype and the ASSIST scale measures. There was no
significant association between the STin2.12 allele and alco-
hol use risk (29/255 versus 4/72, χ2 = 1.76, df = 1, p =
0.184), risk for sedative use (11/273 versus 3/73, χ2 = 0.00,
df = 1, p = 0.976) or either sedative or alcohol use risk (37/
247 versus 7/69, χ2 = 0.81, df = 1, p = 0.367). There was no
significant association between the STin2.10/10 genotype
and sedative use risk (4/71 versus 29/256, χ2 = 1.67, df = 1,
p = 0.196), risk for sedative use (3/72 versus 11/274, χ2 =
0.00, df = 1, p = 0.955) or either sedative or alcohol use risk
(7/68 versus 37/248, χ2 = 0.81, df = 1, p = 0.391).
Discussion
The major finding of this study is that the Stin2.10/10
genotype decreased risk whereas the STin2.12 allele in-
creased risk to tobacco use disorder. Our results are in
agreement with a previous report showing that carrying
the STin2.10 allele was more common in non-smokers
compared with smokers, showing a protective effect of
this allele [7]. Our results also extend previous findings
on a “significant excess of the 5-HTTLPR long allele
with the 12-repeat VNTR in smokers” [26]. In another
study, it was found that allele 10 carriers were less
prevalent in smokers than in non-smokers, indicating a
protective effect of the STin2.10 allele [7]. Our results
are not in agreement with those of Alves de Lima et al.
[7] who found that subjects carrying STin2. 9 allelecarriers were more prevalent in smokers than in non-
smokers. These contradictory results may be explained
by differences in study populations. Thus while our
study and that of Alves de Lima et al. [7] were both per-
formed in a Brazilian population, the latter authors ex-
amined smokers with and without cancer, whereas in
our study no cancer patients were included but instead
more subjects with affective disorders.
In our study we found that patients with current to-
bacco use disorder showed a significantly increased
prevalence of mood disorders, more work related dis-
ability and a lower education level than never-smokers.
These results are consistent with previous reports which
showed that current smoking is associated with subse-
quent depressive disorders, increased work disability and
lower education levels [32,34,35,41]. Lower educational
levels are additionally associated with the initiation of
tobacco use disorder and with an increased risk to be
unable to quit smoking [5]. Nevertheless, even after con-
sidering the effects of mood disorders and years of edu-
cation the association between tobacco use disorder and
the ST2in polymorphism remained significant.
The second major finding of this study is that there
were no significant associations between the STin2 al-
leles or genotypes and either successful smoking cessa-
tion at week 52 or smoking characteristics, such as age
at onset, duration of tobacco smoking, severity of to-
bacco smoking, number of cigarettes/day or packs/year
etc. These negative findings extend those of a previous
study showing that the SLC6A4 gene is not a major de-
terminant associated with attempts to quit smoking [19].
As Kremer et al. [26] we detected a highly significant as-
sociation between the 5-HTT and the case-definitions of
tobacco use disorder (in our study) or smoking (in Kre-
mer’s study), but not with dependency levels or smoking
characteristics. Therefore, we may conclude as Kremer
et al. [26] that this polymorphism influences the patho-
genesis of tobacco use disorder or nicotine dependence.
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bacco use disorder may also modulate cessation at-
tempts. Thus, one study tested the effects of genetic risk
in a cohort that initiated smoking during adolescence
progressed to daily smoking and progressed to heavy
smokers and developed nicotine dependence. The authors
examined the effects of the SNP of the q 25.1 region of
chromosome 15 containing the nicotinic cholinergic recep-
tor CHRNA5, CHRNA3, CHRNB4 gene cluster. Genetic
risk score was related to individuals who were more likely
to develop nicotine dependence and were more likely to fail
in their cessation attempts [3]. In addition, serum cotinine
levels were associated with a CHRNA genetic polymorph-
ism [49]. Genome wide association studies of tobacco ad-
diction have also identified genes that affect smoking
initiation, these genes being associated with a brain-derived
neurotrophic factor (BDNF) polymorphism on chromo-
some 11 [50]. These findings are consistent with the idea
that different genes are associated with the development
and progression of smoking behavior from initiation, nico-
tine dependence, daily smoking to smoking cessation.
The results of this study add to the knowledge that to-
bacco use disorder is a complex behavior that includes
polygenic risk. Several regions across the genome have
been implicated in containing genes that confer liability
to tobacco use disorder or nicotine dependence and
variation in individual genes has been associated with
nicotine dependence. Regarding the interplay between
genetic and environmental influence on the etiology of
nicotine dependence, studies of twins found that 50% of
the risk of nicotine dependencies was genetically trans-
mitted [51]. More specifically, the STin2.12 allele may be
a transcriptional enhancer associated with an increased
susceptibility to substance abuse [28]. There is evidence
that the STin2.12 allele may have a higher transcrip-
tional activity than the 10-repeat allele [38] and that
STin2.12 allele homozygotes show lowered serotonin
availability [30]. Nicotine is known to increase the re-
lease and signaling of serotonin [52,53]. This may sug-
gest that disorders in 5-HTT functioning and 5-HT
signaling may play a role in nicotine dependence or
withdrawal [52]. Antidepressants, such as selective sero-
tonin reuptake inhibitors, have, however no efficacy in
quitting smoking [54]. In a brain imaging study, there
were no associations between STin.2 genetic polymorph-
ism and the availability of the 5-HTT in different brain
regions [55].
Nevertheless, smoking causes activated immune-
inflammatory and oxidative and nitrosative stress
(IO&NS) pathways [15,34-36]. Activated IO&NS path-
ways, in turn, may induce indoleamine 2,3-dioxygenase
(IDO) leading to increased levels of tryptophan catabo-
lites (TRYCATs), including kynurenine [56], and low-
ered levels of tryptophan and thus serotonin [37].Therefore the lowered availability of serotonin associ-
ated with the STin2.12 allele may be aggravated by
smoking-induced IDO activation. Such IO&NS and
IDO responses are strongly related to depression and
depressive symptoms in patients with tobacco use dis-
orders [56,57]. Nicotine abuse may then be regarded as
an operationally conditioned response that counteracts
depleted serotonin levels thus preventing the adverse
effects of lowered serotonin. Smoking-induced activa-
tion of IO&NS pathways may further endanger sero-
tonin metabolism thereby maintaining nicotine abuse
and thus tobacco use disorder. Therefore, it is likely
that the 5-HTT genes may contribute to the develop-
ment of tobacco use disorder or nicotine dependence
among individuals who are prone to mood disorders or
have a lower educational level. In addition, the effects
of nicotine use on serotonin, and smoking- and STin2-
related changes in the IO&NS-serotonin nexus may
activate (neuro)degenerative pathways related to dys-
functions in the hypothalamic-pituitary-adrenal (HPA)
axis, microglial activation, mitochondrial dysfunctions,
decreased levels of antioxidants, damage to lipids, proteins,
and DNA leading to autoimmune responses against mul-
tiple neoantigens [56,57]. Future research should examine
the relationships between IO&NS pathways and serotonin
signaling in tobacco use disorder and nicotine-dependence.
A third major finding is that no significant association
could be established between STin2 polymorphism and
alcohol use and sedative use risk. Nevertheless, STin2
polymorphism was associated with tobacco use disorder
and tobacco use disorder with increased alcohol and
sedative use risk. This may indicate that the STin 2
VNTR polymorphism in the SLC6A4 gene could influence
an individual’s vulnerability to develop tobacco use disorder
rather than a substance use disorder. Phrased differently,
the STin2.12 allele and STin2.10/10 genotype may be spe-
cifically associated with tobacco use disorder. However, we
used the ASSIST scale to measure increased risk to alcohol
and sedative use rather than DSM IV diagnostic criteria
and therefore the results should be checked using DSMV
criteria of substance abuse disorder.
The results of this study should be interpreted with re-
gard to its strengths and limitations. Firstly, the present
study design was a case–control study and therefore our
results can only delineate associations and not causality.
Secondly, our sample included smokers who had sought
smoking cessation treatment, while women are more
likely to seek assistance for smoking cessation than men.
Therefore, our sample may not be representative of
the general population. Thirdly, the age of our sample
ranged from 18 to 65 years old and therefore our find-
ings cannot be generalized to older or younger popula-
tion. Fourthly, in this study we did not examine other
polymorphisms in the SLC6A4 gene.
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Our findings provide some evidence that a lower fre-
quency of the STin2.10/10 genotype and a higher fre-
quency of the STin2.12 allele are more frequent among
individuals with current tobacco use disorder than in
never-smokers, suggesting that this 5-HTT polymorph-
ism is related to the serotonergic pathophysiology of to-
bacco use disorder and nicotine dependence and the
consequences of smoking activating IO&NS pathways.
The 5-HTT polymorphism does not appear to be a
major determinant of smoking cessation or smoking
characteristics, suggesting that this polymorphism is re-
lated to the pathogenesis of tobacco use disorder or
nicotine dependence. This 5-HTT polymorphism may
be more specific to tobacco use disorder rather than to
substance abuse disorder. The translational implications
of these findings include the identification of subgroups
of patients with current tobacco use disorder, for ex-
ample, those with a serotonergic pathophysiology and
those who are more at risk to develop mood disorders.
Elucidating the influence of the 5-HTT gene polymorph-
ism is important among patients with current tobacco
use disorder because smoking may reinforce the dys-
functions in serotonergic signaling through induction of
IO&NS pathways.
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